logo
Twitter
Discord
Email
logo
Doximity, Inc.

Doximity, Inc.

NYSE•DOCS
CEO: Mr. Jeffrey A. Tangney
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Listing Date: 2021-06-24
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with digital tools built for medicine, that enables its members to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. It primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Contact Information
500 3rd Street, Suite 510, San Francisco, CA, 94107, United States
650-549-4330
www.doximity.com
Market Cap
$8.58B
P/E (TTM)
33.9
35.7
Dividend Yield
--
52W High
$85.21
52W Low
$43.21
52W Range
6%
Rank34Top 20.2%
5.1
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Average • 5.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025

Financial Dashboard

Q2 2026 Data

Revenue

$168.53M+23.16%
4-Quarter Trend

EPS

$0.33+37.50%
4-Quarter Trend

FCF

$93.94M+40.63%
4-Quarter Trend

2026 Q2 Earnings Highlights

Key Highlights

Six Month Revenue Growth Six months revenue reached $314.4M, showing strong 19% growth compared to $263.5M last year.
Net Income Margin Expansion Six months net income was $115.4M; net income margin expanded to 37% from 32% previously.
Key Customer Cohort Growth Key customer cohort grew to 121 accounts, up from 104, representing 84% of trailing twelve-month revenue.
Retention Rate Improvement Net revenue retention rate hit 118%, up from 116%, indicating strong customer expansion and low churn.

Risk Factors

Ongoing Litigation Exposure Subject to ongoing securities and derivative lawsuits; resolution could materially affect financial condition and operations.
G&A Expense Spike General and administrative expense jumped 63% for the quarter due to legal expenses and acquisition costs incurred.
Acquisition Integration Risks Growth via acquisitions risks integration failure, potential goodwill impairment, and increased legal/accounting compliance costs.
Future Financing Needs Future capital needs may require external debt or equity financing, potentially adversely affecting financial condition.

Outlook

R&D Expense Increase Expected Expect research and development expenses to increase on an absolute dollar basis supporting platform growth and offerings.
Sales Marketing Expense Growth Expect sales and marketing expense to increase and become the largest expense on an absolute basis going forward.
Stock Repurchase Availability $279.8M remains available for Class A common stock repurchase under the $500M authorized program.
Tax Deduction Impact Management accelerated R&D deduction, decreasing deferred tax assets by approximately $40.4M in the current period.

Peer Comparison

Revenue (TTM)

Universal Health Services, Inc.UHS
$16.99B
+10.2%
Baxter International Inc.BAX
$11.02B
-6.3%
Encompass Health CorporationEHC
$5.80B
+11.1%

Gross Margin (Latest Quarter)

Neurocrine Biosciences, Inc.NBIX
98.2%
-0.5pp
Universal Health Services, Inc.UHS
90.8%
+0.6pp
Doximity, Inc.DOCS
90.3%
+0.2pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
COO$16.79B44.64.5%20.2%
UHS$14.30B10.419.9%33.3%
NBIX$13.66B31.915.8%10.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-0.0%
Flat Growth
4Q Net Income CAGR
-6.2%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 5, 2026
|
EPS:$0.44
|
Revenue:$181.63M
Reports
All Years

  • Form 10-Q - Q2 2026

    Period End: Sep 30, 2025|Filed: Nov 6, 2025|
    Revenue: $168.53M+23.2%
    |
    EPS: $0.33+37.5%
    Miss

  • Form 10-Q - Q1 2026

    Period End: Jun 30, 2025|Filed: Aug 7, 2025|
    Revenue: $145.91M+15.2%
    |
    EPS: $0.28+27.3%
    Miss

  • Form 10-K - FY 2025

    Period End: Mar 31, 2025|Filed: May 20, 2025|
    Revenue: $570.40M+20.0%
    |
    EPS: $1.19+52.6%
    Beat

  • Form 10-Q - Q3 2025

    Period End: Dec 31, 2024|Filed: Feb 6, 2025|
    Revenue: $168.60M+24.6%
    |
    EPS: $0.40+53.8%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $136.83M+20.4%
    |
    EPS: $0.24+50.0%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $126.68M+16.8%
    |
    EPS: $0.22+46.7%
    Meet

  • Form 10-K - FY 2024

    Period End: Mar 31, 2024|Filed: May 23, 2024|
    Revenue: $475.42M+13.5%
    |
    EPS: $0.78+34.5%
    Beat

  • Form 10-Q - Q3 2024

    Period End: Dec 31, 2023|Filed: Feb 8, 2024|
    Revenue: $135.28M+17.4%
    |
    EPS: $0.26+52.9%
    Beat